Nie J, et al. - In patients suffering relapsed/refractory classic Hodgkin lymphoma (cHL) after at least two lines of previous therapy, researchers performed this two-arm, open-label, phase 2 study to evaluate the safety and effectiveness of anti–programmed death-1 (PD-1) camrelizumab alone vs decitabine-primed camrelizumab. They found that in patients with relapsed/refractory cHL who were clinically naïve to PD-1 blockade, decitabine plus camrelizumab resulted in a significantly higher complete remission rate vs camrelizumab alone. In patients with relapsed/refractory cHL, resistance to PD-1 inhibitors could be reversed by decitabine plus camrelizumab. Complete remission rate was 32% with camrelizumab monotherapy vs 71% who were administered decitabine plus camrelizumab, in anti–PD-1–naïve patients. The most common adverse events with both regimens were clinically inconsequential cherry hemangiomas and leukocytopenia that were self-limiting.